{"id":"W2772776690","doi":"10.1111/jdv.14738","title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's College Hospital; University of Toronto; Probity Medical Research; Queen's University","funders":"Galderma; Dermira; Celgene; GlaxoSmithKline; Biogen; Kyowa Hakko Kirin; Eli Lilly and Company; Astellas Pharma; Astellas Pharma US; Amgen","keywords":"Apremilast; Medicine; Psoriasis; Etanercept; Dermatology Life Quality Index; Placebo; Dermatology; Internal medicine; Visual analogue scale; Psoriasis Area and Severity Index; Adverse effect; Psoriatic arthritis; Surgery; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001824563,0.0002651898,0.00105417,0.0001478633,0.000275054,0.0005191752,0.0002118997,0.0004459862,0.001631181],"category_scores_gemma":[0.001912235,0.000203367,0.0009996744,0.000210113,0.0002839941,0.000439219,0.0001871186,0.001028632,0.0002556696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003389287,"about_ca_system_score_gemma":0.0004552322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002465906,"about_ca_topic_score_gemma":0.0005640131,"domain_scores_codex":[0.9993314,0.0003400972,0.00005893889,0.00008765553,0.0001213896,0.0000605071],"domain_scores_gemma":[0.9984415,0.0004677568,0.0005347707,0.0001031993,0.00008958406,0.0003631589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.589803,0.009988368,0.227089,0.0007333496,0.002807248,0.0004180371,0.000376809,0.0007370919,0.01754588,0.0001034935,0.002127689,0.1482701],"study_design_scores_gemma":[0.2159281,0.2225649,0.5505452,0.0001425659,0.001950469,0.001508381,0.0001714496,0.001142225,0.002125239,0.000209175,0.003656032,0.00005622041],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976026,0.00140892,0.00008711954,0.0001048857,0.00001800452,0.00008936295,0.0001708678,0.000007289026,0.0005110421],"genre_scores_gemma":[0.9984319,0.0004962349,0.0001760773,0.0002399665,0.00005000876,0.00008540812,0.0002893996,0.000002112327,0.0002288879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001824563,"threshold_uncertainty_score":0.009649277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02100902211503499,"score_gpt":0.2506462612993274,"score_spread":0.2296372391842924,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}